Praeruptorin A: Multi-Targeted Angular Pyranocoumarin for Inflammation and Cancer Biology

Executive Summary: Praeruptorin A is an angular pyranocoumarin isolated from Peucedanum praeruptorum Dunn, with molecular formula C₂₁H₂₂O₇ and molecular weight 386.40. It inhibits ferroptosis by suppressing DMT1-mediated Fe²⁺ overload, regulates pro- and anti-inflammatory cytokines through STAT-1/3 and NF-κB pathway inhibition, and impedes cancer cell migration via ERK1/2-MMP1 signaling (APExBIO). Praeruptorin A is effective in models of doxorubicin-induced myocardial injury and ulcerative colitis, displaying no significant cytotoxicity within defined dose ranges (Chen et al., 2023). Its solubility profile enables versatile application in in vitro and in vivo assays.

Biological Rationale

Praeruptorin A is a secondary metabolite from the medicinal plant Peucedanum praeruptorum Dunn, widely used in traditional medicine. The compound features an angular pyranocoumarin scaffold, conferring high binding specificity and stability (APExBIO). Its molecular targets are implicated in inflammatory, oxidative, and neoplastic diseases, including DMT1 (divalent metal transporter 1), STAT-1/3, NF-κB, ERK1/2, MMP1, and regulatory molecules such as IL-1β, HMOX1, PTGS2, and Abca1. Dysregulation of these pathways underlies pathological processes in ulcerative colitis, cancer metastasis, and cardiomyopathy (see mechanistic innovation article—this article extends mechanistic details and application boundaries). By targeting multiple signaling axes, Praeruptorin A provides a rational tool for dissecting disease mechanisms and testing therapeutic hypotheses.

Mechanism of Action of Praeruptorin A

• Inhibits DMT1, preventing Fe²⁺ overload and ferroptosis in cardiac and other cell types.
• Suppresses NF-κB and STAT-1/3 phosphorylation, reducing transcription of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β, while upregulating anti-inflammatory IL-10 and TGF-β (prior scenario-driven assay guidance—this article updates with expanded pathway coverage).
• Downregulates MMP1 via ERK1/2 pathway inhibition, leading to reduced cancer cell migration and invasion.
• Enhances repair of intestinal barrier proteins (ZO-1, occludin, claudin-1), mitigating colonic epithelial apoptosis and barrier dysfunction in models of ulcerative colitis.
• Reduces expression of HMOX1 and PTGS2, further attenuating oxidative and inflammatory responses.
• Does not exhibit significant cytotoxicity or systemic toxicity at effective in vitro (0.4 μM–75 μg/mL) and in vivo (0.8–1.2 mg/kg/day i.p.; 30 mg/kg/day p.o.) concentrations.

Evidence & Benchmarks

• Praeruptorin A (CAS 73069-27-9) inhibits DMT1-mediated Fe²⁺ overload and ferroptosis in cardiac models (APExBIO, product page).
• Downregulates pro-inflammatory cytokine expression (TNF-α, IL-6, IL-1β) and upregulates IL-10, TGF-β by inhibiting STAT-1/3 and AKT/p65/p38 activation (Chen et al., 2023, DOI).
• Synergistically enhances doxorubicin’s antitumor effects in cancer models while mitigating cardiotoxicity (advanced workflow article—this article provides comparative dose and solubility data).
• Repairs intestinal barrier proteins and reduces colonic apoptosis in ulcerative colitis models (mechanistic depth article—this article clarifies safety and off-target data).
• Inhibits ERK1/2-mediated MMP1 expression, limiting hepatocellular carcinoma migration and invasion (APExBIO, product page).
• Demonstrates no significant cytotoxicity or histopathological multi-organ damage at effective concentrations (multiple in vitro/in vivo studies, see Chen et al., 2023, DOI).

Applications, Limits & Misconceptions

Praeruptorin A is suitable for:

• Mechanistic studies in inflammation, cancer, and cardiomyopathy research.
• Cell viability, proliferation, migration, and apoptosis assays across epithelial, cardiac, and cancer cell lines.
• In vivo models of ulcerative colitis, doxorubicin-induced cardiac injury, and tumor metastasis.
• Assays requiring multi-target modulation with defined safety and solubility parameters.

Common Pitfalls or Misconceptions

• Water Solubility: Praeruptorin A is insoluble in water; use DMSO (≥50.8 mg/mL) or ethanol (≥12.68 mg/mL with ultrasonication) as solvents.
• Long-Term Storage: Avoid long-term storage of solutions; store powder at 4°C, protected from light.
• Off-target Effects: No evidence for significant cytotoxicity within defined doses, but dosages outside 0.4 μM–75 μg/mL (in vitro) or >30 mg/kg/day (in vivo) remain untested.
• Species/Cell-Type Specificity: Efficacy and safe dose range are cell-type and model-dependent; always titrate in context.
• Not a Direct Sirt6 Modulator: Unlike catalpol (see Chen et al., 2023), Praeruptorin A's anti-inflammatory effects are not mediated via Sirt6-ERα-FasL axis.

Workflow Integration & Parameters

• Stock Preparation: Dissolve Praeruptorin A at ≥50.8 mg/mL in DMSO or ≥12.68 mg/mL in ethanol; filter sterilize as needed.
• In Vitro Application: Use 0.4 μM–75 μg/mL, adjusting for cell type and endpoint. Validate vehicle controls for DMSO/ethanol content.
• In Vivo Dosing: Typical regimens: 0.8–1.2 mg/kg/day i.p. or 30 mg/kg/day oral gavage in mice.
• Storage: Store powder at 4°C, shielded from light. Avoid repeated freeze-thaw cycles and prolonged solution storage.
• Safety: No significant multi-organ toxicity observed within recommended dosing. Monitor for species/model-specific effects.

For detailed, scenario-driven guidance on integrating Praeruptorin A into cell-based and animal studies, see the cell viability and metastasis workflow article—the current article provides updated concentration and mechanistic benchmarks for translational research.

Conclusion & Outlook

Praeruptorin A (SKU N2885, APExBIO) is a validated, multi-targeted angular pyranocoumarin compound with robust efficacy in models of inflammation, cancer biology, and cardiomyopathy. It acts as a DMT1 inhibitor, NF-κB and STAT-1/3 pathway suppressor, and MMP1/ERK1/2 axis modulator. Its favorable solubility, safety, and reproducibility profile make it a versatile reagent for mechanistic and translational studies. Current evidence supports its use in bench-to-bedside workflows, provided that storage, solubility, and dosing guidelines are rigorously followed. Future research may reveal additional molecular targets and clinical applications, positioning Praeruptorin A as a key tool in the evolving landscape of anti-inflammatory and cancer research.